双重作用的组蛋白去乙酰化酶-拓扑异构酶 I 抑制剂。
Dual-acting histone deacetylase-topoisomerase I inhibitors.
机构信息
School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
出版信息
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3283-7. doi: 10.1016/j.bmcl.2013.03.108. Epub 2013 Apr 4.
Abstract
Current chemotherapy regimens are comprised mostly of single-target drugs which are often plagued by toxic side effects and resistance development. A pharmacological strategy for circumventing these drawbacks could involve designing multivalent ligands that can modulate multiple targets while avoiding the toxicity of a single-targeted agent. Two attractive targets, histone deacetylase (HDAC) and topoisomerase I (Topo I), are cellular modulators that can broadly arrest cancer proliferation through a range of downstream effects. Both are clinically validated targets with multiple inhibitors in therapeutic use. We describe herein the design and synthesis of dual-acting histone deacetylase-topoisomerase I inhibitors. We also show that these dual-acting agents retain activity against HDAC and Topo I, and potently arrest cancer proliferation.
摘要
目前的化疗方案主要由单靶点药物组成，这些药物常常受到毒性副作用和耐药性发展的困扰。一种规避这些缺点的药理学策略可能涉及设计多价配体，这些配体可以调节多个靶点，同时避免单靶点药物的毒性。组蛋白去乙酰化酶（HDAC）和拓扑异构酶 I（Topo I）是两种有吸引力的靶点，它们是细胞调节剂，可以通过一系列下游效应广泛阻止癌细胞增殖。这两个靶点都是经过临床验证的靶点，有多种抑制剂在治疗中使用。本文描述了双作用组蛋白去乙酰化酶-拓扑异构酶 I 抑制剂的设计和合成。我们还表明，这些双作用试剂保留了对 HDAC 和 Topo I 的活性，并能有效地抑制癌症的增殖。
相似文献
1
Dual-acting histone deacetylase-topoisomerase I inhibitors.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3283-7. doi: 10.1016/j.bmcl.2013.03.108. Epub 2013 Apr 4.
2
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.
3
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Eur J Med Chem. 2018 Jan 1;143:2005-2014. doi: 10.1016/j.ejmech.2017.11.021. Epub 2017 Nov 8.
4
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
5
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Bioorg Med Chem. 2018 Aug 7;26(14):3958-3966. doi: 10.1016/j.bmc.2018.06.016. Epub 2018 Jun 20.
6
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
PLoS One. 2018 Oct 9;13(10):e0205018. doi: 10.1371/journal.pone.0205018. eCollection 2018.
7
3-Arylisoquinolines as novel topoisomerase I inhibitors.
Bioorg Med Chem. 2011 Jan 15;19(2):724-34. doi: 10.1016/j.bmc.2010.10.057. Epub 2010 Nov 2.
8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Bioorg Med Chem. 2018 May 1;26(8):1920-1928. doi: 10.1016/j.bmc.2018.02.042. Epub 2018 Feb 27.
9
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Bioorg Med Chem Lett. 2017 Feb 15;27(4):744-749. doi: 10.1016/j.bmcl.2017.01.044. Epub 2017 Jan 17.
10
Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Chem Biodivers. 2012 Jun;9(6):1084-94. doi: 10.1002/cbdv.201100195.
引用本文的文献
1
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.
Pharmaceuticals (Basel). 2025 Feb 27;18(3):341. doi: 10.3390/ph18030341.
2
MolBiC: the cell-based landscape illustrating molecular bioactivities.
Nucleic Acids Res. 2025 Jan 6;53(D1):D1683-D1691. doi: 10.1093/nar/gkae868.
3
Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions.
Molecules. 2023 Jun 22;28(13):4931. doi: 10.3390/molecules28134931.
4
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer.
ACS Omega. 2023 May 1;8(19):16532-16544. doi: 10.1021/acsomega.3c00222. eCollection 2023 May 16.
5
Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.
Ann Med. 2023 Dec;55(1):2203946. doi: 10.1080/07853890.2023.2203946.
6
First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
J Med Chem. 2022 Nov 10;65(21):14764-14791. doi: 10.1021/acs.jmedchem.2c01276. Epub 2022 Oct 28.
7
Research Advances on Anti-Cancer Natural Products.
Front Oncol. 2022 May 6;12:866154. doi: 10.3389/fonc.2022.866154. eCollection 2022.
8
R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.
Mol Cancer Res. 2021 Aug;19(8):1361-1374. doi: 10.1158/1541-7786.MCR-20-0833. Epub 2021 May 28.
9
Application of Amino Acids in the Structural Modification of Natural Products: A Review.
Front Chem. 2021 Apr 29;9:650569. doi: 10.3389/fchem.2021.650569. eCollection 2021.
10
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Cancers (Basel). 2021 Feb 5;13(4):634. doi: 10.3390/cancers13040634.
本文引用的文献
1
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3.
2
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
3
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
J Med Chem. 2010 Aug 26;53(16):6100-11. doi: 10.1021/jm100507q.
4
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
Bioorg Med Chem. 2010 Jan 1;18(1):415-25. doi: 10.1016/j.bmc.2009.10.042. Epub 2009 Oct 27.
5
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.
Mol Cancer. 2009 Nov 13;8:101. doi: 10.1186/1476-4598-8-101.
6
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
J Hematol Oncol. 2009 Jul 30;2:33. doi: 10.1186/1756-8722-2-33.
7
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
8
Non-peptide macrocyclic histone deacetylase inhibitors.
J Med Chem. 2009 Jan 22;52(2):456-68. doi: 10.1021/jm801128g.
9
DNA cleavage assay for the identification of topoisomerase I inhibitors.
Nat Protoc. 2008;3(11):1736-50. doi: 10.1038/nprot.2008.174.
10
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Bioorg Med Chem. 2008 May 1;16(9):4839-53. doi: 10.1016/j.bmc.2008.03.050. Epub 2008 Mar 23.
Zotero 插件